|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MALRD1 |
Gene summary for MALRD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MALRD1 | Gene ID | 340895 |
| Gene name | MAM and LDL receptor class A domain containing 1 | |
| Gene Alias | C10orf112 | |
| Cytomap | 10p12.31 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q5VYJ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 340895 | MALRD1 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 1.70e-02 | 5.72e-01 | -0.138 |
| 340895 | MALRD1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 3.02e-18 | 8.80e-01 | -0.2116 |
| 340895 | MALRD1 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 1.35e-09 | 9.69e-01 | -0.1941 |
| 340895 | MALRD1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 3.33e-13 | 1.01e+00 | -0.2107 |
| 340895 | MALRD1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 1.43e-21 | 1.10e+00 | -0.2119 |
| 340895 | MALRD1 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 8.73e-11 | 4.42e-01 | -0.0166 |
| 340895 | MALRD1 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.32e-12 | 4.39e-01 | -0.0132 |
| 340895 | MALRD1 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.04e-11 | 4.21e-01 | -0.013 |
| 340895 | MALRD1 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 3.43e-13 | 4.97e-01 | -0.0121 |
| 340895 | MALRD1 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 6.41e-07 | 8.48e-01 | -0.0961 |
| 340895 | MALRD1 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 4.65e-06 | 7.19e-01 | -0.0876 |
| 340895 | MALRD1 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.72e-04 | 6.59e-01 | -0.0822 |
| 340895 | MALRD1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 6.77e-08 | 7.53e-01 | -0.0809 |
| 340895 | MALRD1 | RNA-P8T2-P8T2-4 | Human | Lung | AIS | 3.35e-03 | 9.34e-01 | -0.1197 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MALRD1 | SNV | Missense_Mutation | novel | c.4300G>A | p.Glu1434Lys | p.E1434K | Q5VYJ5 | protein_coding | tolerated(0.06) | possibly_damaging(0.809) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| MALRD1 | SNV | Missense_Mutation | novel | c.4751N>C | p.Ser1584Thr | p.S1584T | Q5VYJ5 | protein_coding | deleterious(0.04) | probably_damaging(0.968) | TCGA-AC-A2BK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| MALRD1 | SNV | Missense_Mutation | novel | c.4064N>C | p.Phe1355Ser | p.F1355S | Q5VYJ5 | protein_coding | deleterious(0.04) | probably_damaging(0.958) | TCGA-BH-A6R8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MALRD1 | SNV | Missense_Mutation | novel | c.5073N>T | p.Leu1691Phe | p.L1691F | Q5VYJ5 | protein_coding | deleterious(0.04) | probably_damaging(0.991) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
| MALRD1 | SNV | Missense_Mutation | novel | c.2262G>T | p.Met754Ile | p.M754I | Q5VYJ5 | protein_coding | tolerated(0.74) | benign(0.009) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MALRD1 | SNV | Missense_Mutation | c.2657G>A | p.Arg886Lys | p.R886K | Q5VYJ5 | protein_coding | deleterious(0.03) | benign(0.408) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MALRD1 | SNV | Missense_Mutation | novel | c.5236N>G | p.Gln1746Glu | p.Q1746E | Q5VYJ5 | protein_coding | deleterious(0) | benign(0.164) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| MALRD1 | SNV | Missense_Mutation | rs762913209 | c.2858G>A | p.Arg953His | p.R953H | Q5VYJ5 | protein_coding | tolerated(1) | benign(0) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MALRD1 | SNV | Missense_Mutation | novel | c.4321N>A | p.Glu1441Lys | p.E1441K | Q5VYJ5 | protein_coding | deleterious(0.04) | probably_damaging(0.959) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MALRD1 | SNV | Missense_Mutation | novel | c.5681N>A | p.Gly1894Asp | p.G1894D | Q5VYJ5 | protein_coding | deleterious(0.04) | benign(0.109) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |